To validate our in vitro findings, we measured the concentration of soluble Axl (sAxl) in serum samples from 40 patients presenting with HCC and treated with sorafenib between 2011 and 2016 at Imperial College, London as per international guidelines37 until disease progression or unacceptable toxicity. Here, AXL is linked to hepatocellular carcinoma.